Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer

NCT00959127 is registered in ClinicalTrials.gov with Array Biopharma, now a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT00959127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00959127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer
Lead sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2009
Completion date
January 31, 2013
Enrollment
93 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic biliary cancer, advanced solid tumors, metastatic colorectal cancer